Efficacy and Safety of Abrocitinib in Patients With Moderate…
Well Cited
406
Citations36
Refs2020
Year
Search Works
Work Details
- DOI 10.1001/jamadermatol.2020.1406
- PMID https://pubmed.ncbi.nlm.nih.gov/32492087
- PMCID https://www.ncbi.nlm.nih.gov/pmc/articles/7271424
- OpenAlex ID W3032018657
- Type Article
- Language EN
- Published 03 Jun 2020
- Volume 156 (8)
- Pages 863
- Source JAMA Dermatology
- Publisher American Medical Association
- FWCI 43.24
- Countries 4
- Institutions 10
- Added 05 Jun 2020
- Updated 30 Oct 2026
External Links
MENU
0
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Article 2020 EN Hybrid
Importance: Abrocitinib, an oral, once-daily Janus kinase 1 selective inhibitor, was effective and well tolerated in a phase 3 monotherapy trial of patients with moderate-to-severe atopic dermatitis (AD). Objective: To investigate the efficacy and safety of abrocitinib in adolescents and adults with moderate-to-severe AD in an identically designed trial. Design, Setting, and Participants: This pha…
406
Citations
36
References
11
Authors
43.24
FWCI
Citations by Year
Last 8 yearsTopics
Keywords
UN Sustainable Development Goals
1 SDGsAuthors & Affiliations
11 authors| # | Author | Institutions | ORCID |
|---|---|---|---|
| 1 | Jonathan I. Silverberg | George Washington University (US) | |
| 2 | Eric Lawrence Simpson | Oregon Health & Science Univer… (US) | |
| 3 | Jacob Pontoppidan Thyssen | University of Copenhagen (DK) Herlev Hospital (DK) +1 | |
| 4 | Melinda Gooderham | Queen's University (CA) SKiN Health (CA) +1 | |
| 5 | Gary L. Chan | Pfizer (United States) (US) | |
| 6 | Claire Feeney | Pfizer (United Kingdom) (GB) | |
| 7 | Pinaki Biswas | Pfizer (United States) (US) | |
| 8 | Hernán Valdez Corresponding | Pfizer (United States) (US) | |
| 9 | Marco DiBonaventura | Pfizer (United States) (US) | |
| 10 | Chudy I. Nduaka | Pfizer (United States) (US) | — |
| 11 | Ricardo Rojo | Pfizer (United States) (US) | — |
Related Works
10Data: OpenAlex